{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:43Z","timestamp":1791924763274,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcjo.2025.11.009","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:42:59Z","timestamp":1770180179000},"page":"542-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world effectiveness of topical insulin for neurotrophic keratopathy: retrospective case series of 29 eyes"],"prefix":"10.1016","volume":"61","author":[{"given":"Eknoor","family":"Padda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-5320","authenticated-orcid":false,"given":"Mehrshad","family":"Hanafimosalman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Racine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Daigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Massicotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-0137","authenticated-orcid":false,"given":"Mona","family":"Harissi-Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2025.11.009_bib0001","first-page":"989","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0002","first-page":"571","article-title":"Diagnosis and management of neurotrophic keratitis","volume":"8","author":"Sacchetti","year":"2014","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0003","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0004","unstructured":"Current ocular therapy | JAMA Ophthalmology | JAMA Network. Accessed May 15, 2025. https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/article-abstract\/1150454"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/EB.S117261","article-title":"Neurotrophic keratitis: current challenges and future prospects","volume":"10","author":"Versura","year":"2018","journal-title":"Eye Brain"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0006","doi-asserted-by":"crossref","unstructured":"Neurotrophic keratitis | Ophthalmologica | Karger Publishers. Accessed May 15, 2025.https:\/\/karger.com\/oph\/article-abstract\/231\/4\/191\/255551\/Neurotrophic-Keratitis?redirectedFrom=fulltext","DOI":"10.1159\/000354380"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0007","first-page":"603","article-title":"Botulinum toxin A induced protective ptosis","volume":"1","author":"Adams","year":"1987","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICL.0000000000000753","article-title":"Surgical management of the ocular surface in neurotrophic keratopathy: amniotic membrane, conjunctival grafts, lid surgery, and neurotization","volume":"47","author":"Trinh","year":"2021","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0009","first-page":"145","article-title":"Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops","volume":"14","author":"Versura","year":"2016","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/ICL.0000000000000748","article-title":"Scleral lens use in neurotrophic keratopathy: a review of current concepts and practice","volume":"47","author":"Witsberger","year":"2021","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08820538.2013.768678","article-title":"A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis","volume":"29","author":"Turkoglu","year":"2014","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0012","first-page":"78","article-title":"Conjunctival flaps for corneal disease: their usefulness and complications","volume":"67","author":"Gundersen","year":"1969","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0013","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ICU.0b013e3283543b61","article-title":"Nerve growth factor therapy for corneal disease","volume":"23","author":"Lambiase","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0014","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","article-title":"Corneal nerves: structure, contents and function","volume":"76","author":"M\u00fcller","year":"2003","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0015","unstructured":"Orphan status granted for neurotropic keratitis drug\u2014American Academy of Ophthalmology. Accessed May 15, 2025.https:\/\/www.aao.org\/education\/headline\/orphan-status-granted-neurotropic-keratitis-drug"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0016","series-title":"Cenegermin (Oxervate): CADTH reimbursement recommendation: indication: for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults","year":"2022"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.brainresbull.2009.08.024","article-title":"Growth factors and corneal epithelial wound healing","volume":"81","author":"Yu","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0022-4804(92)90121-F","article-title":"Insulin-like growth factors I and II expression in the healing wound","volume":"52","author":"Gartner","year":"1992","journal-title":"J Surg Res"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0019","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1167\/iovs.03-1064","article-title":"Insulin, not leptin, promotes in vitro cell migration to heal monolayer wounds in human corneal epithelium","volume":"45","author":"Shanley","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0020","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ajpath.2020.08.006","article-title":"Insulin promotes corneal nerve repair and wound healing in type 1 diabetic mice by enhancing Wnt\/\u03b2-catenin signaling","volume":"190","author":"Yang","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111611","article-title":"Insulin facilitates corneal wound healing in the diabetic environment through the RTK-PI3K\/Akt\/mTOR axis in vitro","volume":"548","author":"Peterson","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1515\/bmc-2019-0002","article-title":"Insulin promotes wound healing by inactivating NFK\u03b2p50\/p65 and activating protein and lipid biosynthesis and alternating pro\/anti-inflammatory cytokines dynamics","volume":"10","author":"Kaur","year":"2019","journal-title":"Biomol Concepts"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1542-0124(12)70206-9","article-title":"Neurotrophic mediators and corneal wound healing","volume":"3","author":"Nishida","year":"2005","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0024","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jcp.21850","article-title":"IGF-1 released by corneal epithelial cells induces up-regulation of N-cadherin in corneal fibroblasts","volume":"221","author":"Ko","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ghir.2018.02.001","article-title":"Shifting the IGF-axis: an age-related decline in human tear IGF-1 correlates with clinical signs of dry eye","volume":"40","author":"Patel","year":"2018","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0026","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exer.2011.12.006","article-title":"Cellular distribution of the IGF-1R in corneal epithelial cells","volume":"94","author":"Robertson","year":"2012","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0027","first-page":"963","article-title":"Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface","volume":"43","author":"Rocha","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0028","first-page":"208","article-title":"Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients","volume":"68","author":"Bastion","year":"2013","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/joco.joco_32_24","article-title":"Topical insulin for neurotrophic-related epithelial defects: where do we stand? A systematic review","volume":"36","author":"Wouters","year":"2024","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0030","first-page":"418","article-title":"Randomized controlled trial of topical insulin for healing corneal epithelial defects induced during vitreoretinal surgery in diabetics","volume":"6","author":"Fai","year":"2017","journal-title":"Asia-Pac J Ophthalmol Phila Pa"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0031","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/ICO.0000000000002858","article-title":"Topical insulin-utility and results in refractory neurotrophic keratopathy in stages 2 and 3","volume":"41","author":"Soares","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0032","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1111\/aos.14997","article-title":"Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea","volume":"100","author":"Diaz-Valle","year":"2022","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0033","series-title":"StatPearls","article-title":"Cenegermin","author":"Adams","year":"2025"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0034","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/jop.2025.0023","article-title":"Real-world safety profile of cenegermin per FDA adverse event reporting system","volume":"41","author":"Choudhry","year":"2025","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0037","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/ICO.0000000000003308","article-title":"Randomized clinical trial of topical insulin versus artificial tears for healing rates of iatrogenic corneal epithelial defects induced during vitreoretinal surgery in diabetics","volume":"42","author":"Dasrilsyah","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0038","first-page":"208","article-title":"Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients","volume":"68","author":"Bastion","year":"2013","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0039","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1177\/1120672120958307","article-title":"Topical insulin for refractory persistent corneal epithelial defects","volume":"31","author":"Diaz-Valle","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/ICO.0000000000003145","article-title":"Healing of chemical injury-related persistent corneal epithelial defects with topical insulin","volume":"42","author":"Balal","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0041","series-title":"Cenegermin (Oxervate): cadth reimbursement review: therapeutic area: neurotrophic keratitis","year":"2022"},{"key":"10.1016\/j.jcjo.2025.11.009_bib0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pharmaceutics16010015","article-title":"Topical insulin in neurotrophic keratopathy: a review of current understanding of the mechanism of action and therapeutic approach","volume":"16","author":"Jaworski","year":"2024","journal-title":"Pharmaceutics"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225004740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225004740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:37:55Z","timestamp":1781253475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418225004740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0008418225004740"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.11.009","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of topical insulin for neurotrophic keratopathy: retrospective case series of 29 eyes","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}